Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa

Affiliations


Abstract

With the increasing prevalence of obesity and type 2 diabetes, fatty liver disease associated with metabolic dysfunction is a global health problem, especially because it is one of the earliest consequences of obesity and it precedes diabetes development. Fatty liver disease associated with metabolic dysfunction is of particular concern in the Middle East and north Africa, where its prevalence is greater than that in the rest of the world. Despite the magnitude of the problem, no regional guidelines have been developed to address this disease. This Review describes suggestions of redefining fatty liver disease associated with metabolic dysfunction, including its terminology and criteria for diagnosis. Experts have raised serious concerns on the current nomenclature, which labels the disease as non-alcoholic fatty liver disease (NAFLD), and its diagnostic criteria. The panel reached a consensus that the disease should be renamed as metabolic-associated fatty liver disease (MAFLD) and that the disease should be diagnosed by positive criteria. The aim is now to work with authorities across the region to implement these proposed changes and reflect them in health-care policy and to improve health care for patients in this region.


Similar articles

The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease.

Mendez-Sanchez N, Arrese M, Gadano A, Oliveira CP, Fassio E, Arab JP, Chávez-Tapia NC, Dirchwolf M, Torre A, Ridruejo E, Pinchemel-Cotrim H, Castellanos Fernández MI, Uribe M, Girala M, Diaz-Ferrer J, Restrepo JC, Padilla-Machaca M, Dagher L, Gatica M, Olaechea B, Pessôa MG, Silva M.Lancet Gastroenterol Hepatol. 2021 Jan;6(1):65-72. doi: 10.1016/S2468-1253(20)30340-X. Epub 2020 Nov 9.PMID: 33181118 Review.

MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.

Eslam M, Sanyal AJ, George J; International Consensus Panel.Gastroenterology. 2020 May;158(7):1999-2014.e1. doi: 10.1053/j.gastro.2019.11.312. Epub 2020 Feb 8.PMID: 32044314 Review.

Redefining fatty liver disease: an international patient perspective.

Shiha G, Korenjak M, Eskridge W, Casanovas T, Velez-Moller P, Högström S, Richardson B, Munoz C, Sigurðardóttir S, Coulibaly A, Milan M, Bautista F, Leung NWY, Mooney V, Obekpa S, Bech E, Polavarapu N, Hamed AE, Radiani T, Purwanto E, Bright B, Ali M, Dovia CK, McColaugh L, Koulla Y, Dufour JF, Soliman R, Eslam M.Lancet Gastroenterol Hepatol. 2021 Jan;6(1):73-79. doi: 10.1016/S2468-1253(20)30294-6. Epub 2020 Oct 5.PMID: 33031758 Review.

Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019.

Golabi P, Paik JM, AlQahtani S, Younossi Y, Tuncer G, Younossi ZM.J Hepatol. 2021 Oct;75(4):795-809. doi: 10.1016/j.jhep.2021.05.022. Epub 2021 May 31.PMID: 34081959

Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD).

Méndez-Sánchez N, Díaz-Orozco LE.Med Sci Monit. 2021 Jul 12;27:e933860. doi: 10.12659/MSM.933860.PMID: 34248137 Free PMC article.


Cited by

A Review of the Effects of Fucoxanthin on NAFLD.

Sayuti NH, Muhammad Nawawi KN, Goon JA, Mokhtar NM, Makpol S, Tan JK.Nutrients. 2023 Apr 19;15(8):1954. doi: 10.3390/nu15081954.PMID: 37111187 Free PMC article. Review.


References

https://pubmed.ncbi.nlm.nih.gov/